Abstract
Although several molecules have been evaluated as tumor markers of malignant melanoma (MM) progression, there are few available markers sensitive enough to detect recurrence or metastasis. The objective of the present study was to determine clinical significance of serum soluble adhesion molecules in the monitoring of progression in patients with MM. Serum levels of soluble L-selectin (sL-selectin), sE-selectin, sP-selectin, and soluble intercellular adhesion molecule-1 (sICAM-1) were determined by ELISA in 57 MM patients. In a retrospective longitudinal study, nine serum samples from two MM patients were analyzed during a follow-up period of 4.0 and 4.3 years, respectively. Serum sICAM-1 levels in MM patients were significantly higher than those in healthy controls and tended to be elevated as the disease stage progressed. In contrast, serum sL-selectin levels were significantly lower in MM patients compared to healthy controls and tended to decrease as the disease stage progressed. There was no significant difference in serum sE-selectin and sP-selectin levels between MM patients and normal control. In a longitudinal study, increased sICAM-1 and decreased sL-selectin levels were generally associated with the progression of MM. These results suggest that monitoring both sICAM-1 and sL-selectin is available to evaluate the progression of MM.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- MM:
-
Malignant melanoma
- ICAM-1:
-
Intercellular adhesion molecule-1
References
Adams DH, Mainolfi E, Elias E et al (1993) Detection of circulating intercellular adhesion molecule-1 after liver transplantation—evidence of local release within the liver during graft rejection. Transplantation 55:83–87
Altomonte M, Colizzi F, Esposito G, Maio M (1992) Circulating intercellular adhesion molecule 1 as a marker of disease progression in cutaneous melanoma. N Engl J Med 327:959
Banks RE, Gearing AJ, Hemingway IK et al (1993) Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies. Br J Cancer 68:122–124
Becker JC, Dummer R, Hartmann AA et al (1991) Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity. J Immunol 147:4398–4401
Fortis C, Galli L, Consogno G et al (1995) Serum levels of soluble cell adhesion molecules (ICAM-1, VCAM-1, E-selectin) and of cytokine TNF-alpha increase during interleukin-2 therapy. Clin Immunol Immunopathol 76:142–147
Harning R, Mainolfi E, Bystryn JC et al (1991) Serum levels of circulating intercellular adhesion molecule 1 in human malignant melanoma. Cancer Res 51:5003–5005
Hasegawa M, Takata M, Hatta N et al (1997) Simultaneous measurement of serum 5-S-cysteinyldopa, circulating intercellular adhesion molecule-1 and soluble interleukin-2 receptor levels in Japanese patients with malignant melanoma. Melanoma Res 7:243–251
Haznedaroglu IC, Benekli M, Ozcebe O et al (2000) Serum L-selectin and P-selectin levels in lymphomas. Haematologia (Budap) 30:27–30
Hirai S, Kageshita T, Kimura T et al (1997) Serum levels of sICAM-1 and 5-S-cysteinyldopa as markers of melanoma progression. Melanoma Res 7:58–62
Izycka A, Jablonska E, Izycki T, Chyczewska E (2002) Expression of adhesion molecules LFA-1 and L-selectin on PMN and level of soluble sE-selectin and sL-selectin in the serum of patients with small cell lung cancer. Pneumonol Alergol Pol 70:403–408
Kageshita T, Yoshii A, Kimura T et al (1993) Clinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanoma. Cancer Res 53:4927–4932
Leeuwenberg JF, Smeets EF, Neefjes JJ et al (1992) E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 77:543–549
Lynch DF Jr, Hassen W, Clements MA et al (1997) Serum levels of endothelial and neural cell adhesion molecules in prostate cancer. Prostate 32:214–220
Nakatsura T, Kageshita T, Ito S et al (2004) Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res 10:6612–6621
Olejnik I (1999) Serum soluble L-selectin in childhood acute lymphoblastic leukemia. Pediatr Int 41:246–248
Schadendorf D, Diehl S, Zuberbier T et al (1996) Quantitative detection of soluble adhesion molecules in sera of melanoma patients correlates with clinical stage. Dermatology 192:89–93
Scheibenbogen C, Keilholz U, Meuer S et al (1993) Differential expression and release of LFA-3 and ICAM-1 in human melanoma cell lines. Int J Cancer 54:494–498
Tedder TF, Li X, Steeber DA (1999) The selectins and their ligands: adhesion molecules of the vasculature. Adv Mol Cell Biol 28:65–111
Tsujisaki M, Imai K, Hirata H et al (1991) Detection of circulating intercellular adhesion molecule-1 antigen in malignant diseases. Clin Exp Immunol 85:3–8
Tu L, Poe JC, Kadono T et al (2002) A functional role for circulating mouse L-selectin in regulating leukocyte/endothelial cell interactions in vivo. J Immunol 169:2034–2043
Yasasever V, Tas F, Duranyildiz D et al (2000) Serum levels of the soluble adhesion molecules in patients with malignant melanoma. Pathol Oncol Res 6:42–45
Zetterberg E, Richter J (1993) Correlation between serum level of soluble L-selectin and leukocyte count in chronic myeloid and lymphocytic leukemia and during bone marrow transplantation. Eur J Haematol 51:113–119
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yamada, M., Yanaba, K., Takehara, K. et al. Clinical significance of serum levels of soluble intercellular adhesion molecule-1 and soluble L-selectin in malignant melanoma. Arch Dermatol Res 297, 256–260 (2005). https://doi.org/10.1007/s00403-005-0605-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00403-005-0605-5